The object of the study was to examine the usefulness of volume-adjusted prostate-specific antigen (PSA) parameters for prediction of prostate cancer in the patients with intermediate PSA levels. The subjects were 235 patients with intermediate PSA levels (range: 4.1-10.0 ng/ml) whose prostate volume (PV) and prostate transition zone volume (TZV) were evaluated between August 1996 and April 2004. PSA, PV, TZV, PSA density (PSAD) (PSA/PV) and PSA transition zone density (PSATZD) (PSA/TZV) were assessed with the receiver operating characteristic (ROC) curve and the area under the curve (AUC). Simple and multivariate logistic regression analyses were used to analyze the odds ratios of age, PSA, PSAD, PSATZD, PV, TZV, digital rectal examination (DRE) and transrectal ultrasonography (TRUS) findings. Fifty-five patients (23.4%) of 235 patients had biopsyproven prostate cancer. The univariate analysis revealed significant differences in the mean values of age, PSAD, PSATZD, PV, TZV and DRE between the patients with cancer and the non-cancer patients. The ROC curve analysis revealed that PV, TZV, PSAD and PSATZD had significant predictive values as compared with that of PSA. However, there was no difference in AUC between them. The stepwise logistic regression analysis showed that the age, PV, PSATZD and DRE had significant predictive values, and that PSATZD had the most predictive power. In conclusion, both PSAD and PSATZD had significant predictive values in discriminating prostate cancer. Furthermore, the stepwise logistic regression analysis showed that PSATZD had the strongest predictive value.
Introduction
Since the introduction of prostate-specific antigen (PSA) for the early detection of prostate cancer, the diagnosis of prostate cancer has accomplished a dramatic change. On the other hand, because PSA is not a cancer-specific marker and its specificity of cancer prediction is low, especially for the patients with intermediate PSA levels (range ¼ 4.1-10.0 ng/ml), the usefulness of using the PSA value in prostate cancer screening is limited.
To overcome this disadvantage, various analyses have been conducted, for example, PSAD (PSA density; PSA value is divided by prostate volume (PV)), PSATZD (PSA transition zone density; PSA value is divided by prostate transition zone volume (TZV)), PSA velocity, age-specific PSA, free PSA, free/total PSA ratio, complexed PSA (cPSAD; cPSA value is divided by PV). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Regarding the reports on prostate cancer detection in the Japanese population, one study 7 revealed the advantage of PSATZD, whereas others demonstrated the usefulness of the free PSA 9 and cPSAD. 10 Nevertheless, there is no absolute discriminating method for prediction of prostate cancer in the patients with intermediate PSA levels.
In this study, we retrospectively investigated our series of Japanese patients with intermediate PSA levels, and elucidated which volumetric parameters or volumeadjusted PSA parameters are available and useful for discriminating prostate cancer from non-cancer lesions including benign prostatic hyperplasia (BPH).
Methods
Between August 1996 and April 2004, 618 consecutive patients who had doubtful prostate cancer based on abnormal PSA value or digital rectal examination (DRE) findings or transrectal ultrasonography (TRUS) findings underwent systematic prostate needle biopsies at Nara Medical University Hospital. Out of these patients, 235 patients with intermediate PSA levels (range ¼ 4.1-10.0 ng/ml), who underwent measurement of both whole PV and prostate TZV were enrolled in this study. Their mean age was 69.3 years (range ¼ 41-88 years). This study group was selected from a community-based practice, that is not a screening population.
PSA was measured (normal value ¼ 3.7 ng/ml or less) using a TOSOH E-test (kit: AIA-PACK PA, ImmunoEnzymometric Assay, TOSOH Corp., Tokyo, Japan) before performing DRE and TRUS. Patients who had acute or chronic prostatitis, urinary retention, urinary tract infection and indwelling urethral catheter were excluded from this study.
Systematic sextant prostate needle biopsy was performed using an automatic biopsy gun and with an 18-gauge needle under TRUS guidance. For each suspicious region with either DRE or TRUS, additional direct biopsies were also performed. Since March 2003, octant systematic needle biopsy has been adopted, besides the sextant biopsies plus additional two biopsies to the bilateral far peripheral zones. We used a 7.5-MHz biplane transducer. Transaxial imaging and trans-sagittal imaging were performed. PV and TZV were calculated using the formula for a prostate ellipsoid (transverse width Â transverse length Â longitudinal height Â 0.52). PSAD and PSATZD were calculated dividing PSA by PV and TZV, respectively.
Prostate intraepithelial neoplasms and atypia were not considered as prostate cancer. To examine differences in studied factors related to prostate cancer diagnosis between patients with prostate cancer and BPH, univariate analyses were performed for PSA, age, PV, TZV, PSAD and PSATZD using Mann-Whitney's U-test, and for the DRE and TRUS findings using Fisher's probability exact test. Analysis using receiver operating characteristic (ROC) curves was employed for diagnosis of prostate cancer to compare among PSA, PV, TZV, PSAD and PSATZD, and we calculated each area under the curve (AUC), comparing it with the Hanley and McNeil method. 12, 13 In the ROC analysis, the reciprocal plots were adopted for PV and TZV. Furthermore, logistic regression models were used to calculate the odds ratios for prostate cancer diagnosis. Multivariate models were made of significant variables selected from the non-adjusted models. All Po0.05 were considered as statistically significant.
The institutional reviewer board approved this retrospective study, and obtaining informed consent from the patients was exempted in the respect of the aim and methods of this study.
Results
Of 618 patients who underwent systematic prostate needle biopsies, 261 patients (42.2%) proved prostate cancer. Of 618 patients, 305 patients had intermediate PSA levels. Of these 305 patients, 71 patients (23.3%) had biopsy-proven prostate cancer. Of these 305 patients, 235 patients underwent measurement of both PV and TZV. Of these 235 patients, 55 patients (23.4%) had biopsyproven prostate cancer. Of 171 patients (72.8%) who received sextant needle biopsy, 30 patients (17.5%) had biopsy-proven prostate cancer. Conversely, of 64 patients (27.2%) who received octant needle biopsy, 25 patients (39.1%) had biopsy-proven prostate cancer. The cancer detection rate of octant needle biopsy was significantly higher than that of sextant needle biopsy (P ¼ 0.01, Fisher's probability exact test).
The characteristics of 235 patients are shown in Table 1 . Regarding these patients, the mean values of age, PSAD and PSATZD in the prostate cancer group were significantly greater than those in the non-cancer group. On the other hand, the mean levels of both PV and TZV in the prostate cancer group were significantly smaller than those in the non-cancer group.
The DRE findings were a significant predictive factor (Fisher's probability exact test, P ¼ 0.005). However, the TRUS findings were not a significant predictive factor (Fisher's probability exact test, P ¼ 0.347; Table 1 ).
Analysis by ROC curves and AUC
The ROC curve analysis of all 235 patients revealed that both PSAD and PSATZD as well as PV and TZV had significant predictive values when compared with PSA in discriminating prostate cancer (Figure 1 ). However, Volume-adjusted PSA N Tanaka et al there was no significant difference in AUCs among these four parameters (Table 2) . When we set the cut-off values of PV, TZV, PSAD and PSATZD as 50.5, 28.4%, 0.09 and 0.141, respectively, all sensitivities were 100%, and the specificity was 18.9, 16.1, 7.8 and 3.9%, respectively.
The cutoff values of each parameter corresponding to the sensitivity of 100, 94.5 and 89.1% are summarized in Table 3 . On using the cutoff values of PV, TZV, PSAD and PSATZD at 100% sensitivity, the numbers of unnecessary biopsies were 34, 29, 14 and 7, respectively. On using the cut-off values at 89.1% sensitivity of PV, TZV, PSAD and PSATZD, 62, 54, 67 and 75 unnecessary biopsies could be avoided, respectively (Table 3) .
On the other hand, when all patients were classified into two groups according to the number of biopsy cores (i.e., sextant or octant biopsy), these two patient groups showed similar AUCs of both PSAD and PSATZD and no influence on AUCs of PSAD and PSATZD was observed in each statistical analysis corresponding to the number of biopsy cores.
Univariate and multivariate analysis on predictive values using age, volume parameters and volume-adjusted PSA parameters
The results of simple logistic regression analyses are shown in Table 4 . Except for PSA and TRUS finding, the age, PV, TZV, PSAD and PSATZD had significant predictive values.
Using the multiple logistic regression analyses, we made four models with PV, TZV, PSAD and PSATZD, separately, and adjusted for the age and DRE findings. All theses four models were significant for prostate cancer diagnosis (Table 5) . As compared to their R 2 value, the value in the PSTZD model was slightly higher than that in the other three models (R 2 value; PV ¼ 0.133, TZV ¼ 0.094, PSAD ¼ 0.108 and PSATZD ¼ 0.150).
The stepwise logistic regression analysis using all six parameters that showed significant predictive values in simple logistic regression analysis revealed that age, PV, PSATZD and DRE showed significant predictive values (P-value; age ¼ 0.021, PV ¼ 0.046, PSATZD ¼ 0.009 and DRE ¼ 0.016; Table 6 ).
Discussion
To improve the cancer detection rate in the patients with intermediate PSA levels, various volume-adjusted parameters such as PSAD, PSATZD, cPSAD, cPSATZD and serum PSA parameters such as free PSA, cPSA have been examined and reported. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Regarding the volume- Volume-adjusted PSA N Tanaka et al adjusted parameters, PSAD and PSATZD were considered as significant predictive factors. Kikuchi et al. 7 reported that PSATZD has the most useful validity among PSA, free PSA to total PSA ratio, alpha-1-antichymotripsin-PSA complex, PSAD and PSATZD. These results could be seen not only in the patients with intermediate PSA levels but also in the entire patient population. Kang et al.
11 also concluded that PSATZD may be more useful than the other parameters in detecting prostate cancer in the patients with intermediate PSA levels. Djavan et al. 6 reported that PSATZD was more effective in prostates greater than 30 cm 3 in volume. Theoretically, PSATZD seems to have an advantage over PSAD especially for the relatively larger prostate to discriminate prostate cancer from BPH.
On the other hand, Matsuyama et al. 9 reported that the percent free PSA was a significant useful predictor in the Japanese patients with intermediate PSA levels and normal DRE findings among PSAD, PSATZD, PV and percent free PSA in discriminating prostate cancer from BPH. Djavan et al. 6 also reported that the free PSA was more effective in prostates less than 30 cm 3 in volume. Egawa et al. 5 reported that the usefulness of both PSAD and PSATZD was similar in cancer detection for the patients with intermediate PSA levels.
In this study, we demonstrated that PSAD has a similar usefulness as PSATZD in the ROC curve analysis. Our results support those of Egawa et al. 5 emphasizing that the usefulness of both PSAD and PSATZD was similar in cancer detection for the patients with intermediate PSA levels. Furthermore, our results suggest that both PV and TZV also have significant predictive values as well as both PSAD and PSATZD in the ROC curve analysis.
Nonetheless, the stepwise logistic regression analysis showed that the age, PV, PSATZD and DRE had significant predictive values in cancer detection. In addition, PSATZD had the most significant predictive value. These results support those of Kikuchi et al. 7 There would be a criticism for using PV, TZV, PSAD and PSATZD in the same model, because these parameters have significant correlations with each other, for example, between PV and PSAD, as well as between TZV and PSATZD.
To prevent these influences, we compared four models with PV, TZV, PSAD and PSATZD, separately, and adjusted them for age and DRE. In the logistic regression analyses, all four models had a significant efficacy to discriminate prostate cancer from BPH. The goodness of fit (R 2 value) in the model including PSATZD showed the largest value, and that in the model including PV showed the second largest value. These findings seem to support the result of the stepwise logistic regression analysis.
Eventually, we could make sure that PSAD and PSATZD are useful predictive tools to discriminate prostate cancer from non-cancer lesions, and we think that the general urologists may be aware about both PV and TZV. We believe that PSATZD would have the most predictive power to discriminate prostate cancer from noncancer lesions.
There may be several criticisms concerning this study. First, this study was a retrospective study. Second, we altered the method of biopsy from sextant to octant. In this study, the cancer detection rate of octant needle biopsy group was significantly higher than that of sextant needle biopsy group. However, of 25 patients with prostate cancer proved on the octant needle biopsies, only one patient revealed prostate cancer in the far lateral peripheral zones without any positive cores in the conventional sextant biopsy zones, and the remaining 24 patient had prostate cancer only in the conventional sextant biopsy zones. Therefore, it was unlikely that the higher cancer detection rate in octant biopsy group was attributed to the additional cores in the far lateral peripheral regions. The reason why the cancer detection rate was higher in octant biopsy group might be that, in spite of the small number of patients (n ¼ 64), the proportion of patients with abnormal DRE finding was unexpectedly higher in octant needle biopsy group than in sextant needle biopsy group (Po0.001). Third, we demonstrated that large prostate had low incidence of prostate cancer. At this moment, we intend to address the following question: Is the number of biopsy cores enough for large prostate? We think that volumeadjusted number of biopsy cores would be necessary. To resolve these problems, further novel prospective studies are necessary.
Conclusion
We conducted this study to examine the efficacy of cancer prediction between PSAD and PSATZD in the 
